Oramed Pharmaceuticals (ORMP) Notes Payables (2020 - 2025)
Oramed Pharmaceuticals filings provide 6 years of Notes Payables readings, the most recent being $652000.0 for Q4 2025.
- Quarterly Notes Payables rose 98.18% to $652000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $652000.0 through Dec 2025, up 98.18% year-over-year, with the annual reading at $652000.0 for FY2025, 98.18% up from the prior year.
- Notes Payables hit $652000.0 in Q4 2025 for Oramed Pharmaceuticals, up from $1000.0 in the prior quarter.
- Across five years, Notes Payables topped out at $75.4 million in Q3 2023 and bottomed at $1000.0 in Q2 2022.
- Average Notes Payables over 5 years is $10.0 million, with a median of $60000.0 recorded in 2021.
- The largest annual shift saw Notes Payables surged 5101200.0% in 2023 before it tumbled 99.95% in 2024.
- Oramed Pharmaceuticals' Notes Payables stood at $66000.0 in 2021, then plummeted by 98.48% to $1000.0 in 2022, then surged by 5101200.0% to $51.0 million in 2023, then tumbled by 99.36% to $329000.0 in 2024, then soared by 98.18% to $652000.0 in 2025.
- Per Business Quant, the three most recent readings for ORMP's Notes Payables are $652000.0 (Q4 2025), $1000.0 (Q3 2025), and $34000.0 (Q2 2025).